More options for ankylosing spondylitis including Taltz

By | translator Byun Kyung A

21.02.06 06:00:37

가나다라 0

Only and first treatment to take ASAS40 as primary endpoint, shows exceptional efficacy

Less complication with cardiovascular condition, “Should be used like TNF-α inhibitor”

The interleukin 17A (IL-17A) inhibitor drugs are taking over the spotlight in the ankylosing spondylitis treatment market. Besides the first-in-class Cosentyx (secukinumab), Taltz (ixekizumab) was released to the South Korean market with its strong evidences. Some specialists predict the guideline, initially recommending the drug to be used after using tumor necrosis factor-alfa (TNF-α) inhibitor, could be changed.

One of the most frequently diagnosed rheumatic diseases, ankylosing spondylitis mostly uses a nonsteroidal anti-inflammatory drug (NSAID). But a biologic drug is recommended for patients with high disease activity.

Humira (adalimumab) and Remicade (infliximab) are TNF-α in

(same@dailypharm.com)

If you want to see the full article, please JOIN US (click)